Difficulties in choosing a biologic disease-modifying anti-rheumatic drug for the treatment of psoriasis and psoriatic arthritis
https://doi.org/10.14412/1995-4484-2019-111-115
Abstract
The article presents a clinical observation of a patient with severe psoriasis and psoriatic arthritis. Due to insufficient efficacy of systemic therapy of psoriasis biologic disease-modifying therapy was started, but it was associated with difficulties. Development of erythrodermic form of psoriasis was observed during treatment with infliximab and abatacept was successfully used though it is not registered inRussiafor the treatment of psoriasis.
About the Authors
I. M. Marusenko
Petrozavodsk State University, Medical Institute, Department of Hospital Therapy
Russian Federation
33, Lenin Avenue, Petrozavodsk 185910
Russian Federation
33, Lenin Avenue, Petrozavodsk 185910
N. N. Vezikova
Petrozavodsk State University, Medical Institute, Department of Hospital Therapy
Russian Federation
33, Lenin Avenue, Petrozavodsk 185910
Russian Federation
33, Lenin Avenue, Petrozavodsk 185910
S. N. Kondrichin
Petrozavodsk State University, Medical Institute, Department of Hospital Therapy
Russian Federation
33, Lenin Avenue, Petrozavodsk 185910
Russian Federation
33, Lenin Avenue, Petrozavodsk 185910
N. D. Silvestrov
V.A. Baranov Republican Hospital
Russian Federation
3, Pirgov St., Petrozavodsk 185019
Russian Federation
3, Pirgov St., Petrozavodsk 185019
References
1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(12):496-509. doi: 10.1056/NEJMra0804595
2. Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386:983-94. doi: 10.1016/S0140-6736(14)61909-7
3. Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:569-79. doi: 10.1016/j.rdc.2015.07.003
4. Российское общество дерматовенерологов и косметологов. Общероссийская общественная организация «Ассоциация ревматологов России». Федеральные клинические рекомендации по ведению больных псориатическим артритом. Москва; 2015. С. 41 [Russian society of dermatovenerologists and cosmetologists. All-Russian public organization «Association of Rheumatologists of Russia». Federal clinical guidelines for the management of patients with psoriatic arthritis. Moscow; 2015. P. 41 (In Russ.)].
5. Mease P, Armstrong A. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74:423-41. doi: 10.1007/s40265-014-0191-y
6. Coates L, Kavanaugh A, Mease P, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheum. 2016;68(5):1060-71. doi: 10.1002/art.39573
7. Коротаева ТВ. Прогресс в лечении псориатического артрита. Фарматека. 2015;(7):21-7 [Korotaeva TV. Progress in the treatment of psoriatic arthritis. Farmateka. 2015;(7):21-7 (In Russ.)].
8. Коротаева ТВ, Насонов ЕЛ. Стандарты терапии псориатического артрита. Научно-практическая ревматология 2009;47(3):29-37 [Korotaeva TV, Nasonov EL. Standards of therapy of psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(3):29-37 (In Russ.)]. doi: 10.14412/1995-4484-2009-1310
9. Palfreeman A, McNamee K, McCann F. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther. 2013;7:201-10. doi: 10.2147/DDDT.S32713
10. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668-77. doi: 10.1111/j.1365-2133.2012.11168.x
11. Насонов ЕЛ. Перспективы применения блокатора костимуляции Т-лимфоцитов абатацепта при ревматоидном артрите. Клиническая фармакология и терапия. 2009;(1):45-52 [Nasonov EL. Prospects for the use of an abatacept T-lymphocyte costimulation blocker in rheumatoid arthritis. Klinicheskaya Farmakologiya i Terapiya. 2009;(1):45-52 (In Russ.)].
12. Moreland LW, Alten R, van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dosefinding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46(6):1470-9. doi: 10.1002/art.10294
13. Муравьев ЮВ. Какие неблагоприятные реакции на генноинженерные биологические препараты относят к парадоксальным? Научно-практическая ревматология. 2018;56(4):531-4 [Muravyev YuV. What adverse reactions to biological agents are paradoxical? Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(4):531-534 (In Russ.)]. doi: 10.14412/1995-4484-2018-531-534
14. Viguier M, Richette P, Bachelez H, et al. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol. 2009;5:421-31. doi: 10.1586/eci.09.18
15. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996-1001. doi: 10.1002/art.23835
16. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-40. doi: 10.1016/j.semarthrit.2010.04.003
17. Belinchon I, et al. Successful treatment of life-threatening erythrodermic psoriasis with infliximab. J Am Acad Dermatol. 2009;60(3):171.
18. Takahashi MDF, Castro LGM, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol. 2007;157(4):828-31. doi: 10.1111/j.1365-2133.2007.08111.x
19. Livia AT, Antonio JR, Mathias CE, Pozetti EMO. Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis. J Anais Brasil Dermatol. 2017;92(5):743-5. doi: 10.1590/abd1806-4841.20176565
20. Westhovens R, Kremer J, Moreland L, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5 year extended phase IIB study. J Rheumatol. 2009;36:736-42. doi: 10.3899/jrheum.080813
21. Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86-94. doi: 10.1136/annrheumdis-2013-203843
22. Насонов ЕЛ. Фармакотерапия ревматоидного артрита: российские и международные рекомендации. Клиническая фармакология и терапия. 2016;25(1):67-76 [Nasonov EL. Pharmacotherapy of rheumatoid arthritis: Russian and international recommendations. Klinicheskaya Farmakologiya i Terapiya. 2016;25(1):67-76 (In Russ.)].
23. Tanita K, Fujimura T, Kakizaki A, et al. Psoriasiform drug eruption caused by abatacept: immunohistochemical investigation of STAT signaling. Case Rep Dermatol. 2015;7:166-70. doi: 10.1159/000437415
24. Smith J, Cline A, Feldman SR. Advances in Psoriasis. South Med J. 2017;110(1):65-75. doi: 10.14423/SMJ.0000000000000596
25. Коротаева ТВ, Корсакова ЮЛ. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология. 2018;56(1):60-9 [Korotaeva TV, Korsakova YuL. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):60-69 (In Russ.)]. doi: 10.14412/1995-4484-2018-60-69
26. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a sixmonth, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939-48. doi: 10.1002/art.30176
27. Huynh D, Kavanaugh A. Psoriatic Arthritis: Current Therapy and Future Approaches. Rheumatology. 2015;54(1):20-8. doi: 10.1093/rheumatology/keu237
28. Корсакова ЮЛ, Станислав МЛ, Денисов ЛН, Насонов ЕЛ. Устекинумаб – новый препарат для лечения псориаза и псориатического артрита. Научно-практическая ревматология. 2013;51(2):170-80 [Korsakova YuL, Stanislav ML, Denisov LN, Nasonov EL. Ustekinumab is a new drug to treat psoriasis and psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(2):170-80 (In Russ.)]. doi: 10.14412/1995-4484-2013-646
29. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-74. doi: 10.1016/S0140-6736(08)60725-4
30. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-84. doi: 10.1016/S0140-6736(08)60726-6
31. Griffiths CEM, Strober BE, van de Kerkhof P, et al. ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate to severe psoriasis. N Engl J Med. 2010;362:118-28. doi: 10.1056/NEJMoa0810652
32. Amin M, No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol. 2018 Feb;19(1):1-13. doi: 10.1007/s40257-017-0328-3
33. Papp K, Gottlieb AB, Naldi L, et al. Safety Surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706-14.
34. Egeberg A. Safety, efficacy and drug survival of biologics and biosimilars for moderate-tosevere plaque psoriasis. Br J Dermatol. 2018;178(2):509-19. doi: 10.1111/bjd.16102
35. Коротаева ТВ, Логинова ЕЮ. Иммунопатогенетические механизмы действия устекинумаба – нового лекарственного средства для лечения псориатического артрита и псориаза. Современная ревматология. 2015;9(2):51-6 [Korotaeva TV, Loginova EYu. Immunopathogenetic mechanisms of action of ustekinumab, a new drug for treatment of psoriatic arthritis and psoriasis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(2):51-6 (In Russ.)]. doi: 10.14412/1996-7012-2015-2-51-56
36. Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an antiIL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000-6. doi: 10.1136/annrheumdis-2013-204741
37. Kavanaugh A, Puig L, et al, on behalf of the PSUMMIT 1 Study Group. Manitenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res. 2015;67:1739-49. doi: 10.1002/acr.22645
38. McInnes I, Kavanaugh A, Gottlieb A, et al. Ustekinumab in patients with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study. Ann Rheum Dis. 2012;71(Suppl):107-48.
39. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3 multicentre, double blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780-9. doi: 10.1016/S0140-6736(13)60594-2
Review
For citations:
Marusenko I.M., Vezikova N.N., Kondrichin S.N., Silvestrov N.D. Difficulties in choosing a biologic disease-modifying anti-rheumatic drug for the treatment of psoriasis and psoriatic arthritis. Rheumatology Science and Practice. 2019;57(1):111-115. (In Russ.) https://doi.org/10.14412/1995-4484-2019-111-115
Views:
1354
Email this article 